Compare Fortive Corporation Common Stock (FTV) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortive Corporation Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Fortive Corporation Common Stock trades at $57.21 (market cap $17.54B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Fortive Corporation Common Stock is far larger — about 3.6× Travere Therapeutics Inc. Common Stock's market cap, and Fortive Corporation Common Stock pays a 0.48% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fortive Corporation Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FTV | TVTX | |
|---|---|---|
Market Cap | $17.54B | $4.88B |
Volume | 1,898,662 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $64.09 | $67.52 |
52-Week Low | $48.49 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $20.67B | $5.01B |
Dividend Yield | 0.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortive Corporation (FTV) trades at $58.07, up 1.22% today, with a neutral technical signal and a consensus analyst price target of $63.33. The stock shows strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue growth is modest, but profitability remains solid with a 12.38% net income margin. Recent news highlights product launches and a dividend increase, while institutional activity includes mixed buying and selling.
The outlook is cautiously positive, supported by raised 2026 guidance and core growth acceleration. Key risks include competitive pressures and macroeconomic headwinds. Analyst sentiment is mixed, with 36.67% buy ratings, but the stock offers potential upside to the consensus target if execution continues to improve.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fortive Corporation Common Stock
Fortive provides industrial and healthcare technology solutions. Its products and software support measurement, maintenance, worker safety, instrument sterilization, and clinical workflows.
Read more on FTV →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
